For severe or refractory disease, several steroid‐sparing agents as well as biologic therapies such as interleukin (IL)‐1 blockers or tumour necrosis factor‐α (TNF‐α antagonist) have proven effective [9, 10]; however, literature evidence is still scarce and further research is needed to provide valuable insights into the complex pathogenesis of SS, paving the way for promising novel therapeutic strategies. This evidence concerns the gene TNF and synovial sarcoma.